Core Points - A class action lawsuit has been filed against Perrigo Company plc for alleged securities fraud and unlawful business practices [1] - Investors who purchased Perrigo securities during the Class Period can apply to be Lead Plaintiff by January 16, 2026 [2] - Perrigo reported significant financial challenges, including a 50% decline in earnings per share for fiscal year 2023 due to remediation costs in its infant formula business [2] - The company's stock price has experienced significant declines following negative earnings reports and strategic announcements, including a drop of 25.2% to close at $15.10 per share on November 5, 2025, after announcing a strategic review of its infant formula business [3] Financial Performance - For fiscal year 2023, Perrigo incurred one-time cash costs of $35 million to $45 million related to production issues in its infant formula business [2] - The adjusted gross profit for the second quarter ended June 28, 2025, decreased by $30 million, or 6.9%, attributed to production variability in infant formula [3] - The stock price fell by $4.87 per share (15.14%) on February 27, 2024, and by $3.28 per share (9.8%) on May 7, 2024, following negative earnings reports [2][3]

Core Viewpoint - Rosen Law Firm has initiated a class action lawsuit against Perrigo Company plc, alleging that the company misled investors regarding its business operations and financial health during the specified Class Period from February 27, 2023, to November 4, 2025 [1][2]. Allegations - The lawsuit claims that Perrigo's infant formula business, acquired from Nestlé, suffered from significant underinvestment in maintenance [3]. - It is alleged that Perrigo needed to incur substantial capital and operational expenditures beyond its stated cost estimates to address issues within the infant formula business [3]. - The lawsuit points out significant manufacturing deficiencies in the facility related to Perrigo's infant formula business [3]. - As a result of these issues, Perrigo's financial results, including earnings and cash flow, were reportedly overstated [3]. - The positive statements made by Perrigo regarding its business operations and prospects were claimed to be materially misleading and lacked a reasonable basis [3]. Class Action Participation - Investors who wish to serve as lead plaintiffs in the class action must file their motions with the court by January 16, 2026 [4]. - Participation in the case is not required to be eligible for recovery; investors can remain absent class members if they choose [4]. Rosen Law Firm Background - Rosen Law Firm is recognized for its commitment to shareholder rights litigation and has recovered over $1 billion for shareholders since its inception [6].

Core Points - A shareholder has filed a securities class action lawsuit on behalf of investors who purchased or acquired securities of Perrigo Company plc between February 27, 2023, and November 4, 2025 [1] - The lawsuit alleges that the defendants made misrepresentations regarding Perrigo's infant formula business acquired from Nestlé [2] Legal Proceedings - Interested parties wishing to serve as lead plaintiff must file papers by January 16, 2026 [3] - Serving as lead plaintiff is not a requirement for sharing in any recovery, and all representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [3] Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented both individual investors and large public and private pension funds [4] - The firm has been recognized for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [4]

Core Points - A shareholder class action lawsuit has been filed against Perrigo Company plc, alleging that the company made materially false and misleading statements regarding its infant formula business acquired from Nestlé [1] - The lawsuit claims significant underinvestment in maintenance and operational improvements in the infant formula business, necessitating substantial capital and operational expenditures beyond stated cost estimates [1] - Allegations include significant manufacturing deficiencies in the infant formula facility, leading to overstated financial results, including earnings and cash flow [1] - The lawsuit asserts that positive statements made by the defendants about the company's business and prospects were materially misleading and lacked a reasonable basis [1] Legal Context - Shareholders who purchased Perrigo shares between February 27, 2023, and November 4, 2025, and experienced significant losses are encouraged to discuss their legal rights [2] - The deadline to request appointment as lead plaintiff in the case is January 16, 2026 [3] - Holzer & Holzer, LLC is representing shareholders in this litigation and has a history of recovering significant amounts for shareholders affected by corporate misconduct [3]

Core Points - A class action has been filed on behalf of investors who purchased or acquired Perrigo Company plc securities between February 27, 2024, and November 4, 2025 [1] - Perrigo Company plc operates in the over-the-counter health and wellness solutions sector, serving markets in the U.S., Europe, and internationally [1]

Core Viewpoint - A securities fraud lawsuit has been filed against Perrigo Company plc by the Law Offices of Frank R. Cruz, indicating potential legal challenges for the company [1] Group 1 - The lawsuit is categorized as a class action, suggesting that it may involve multiple plaintiffs who have suffered losses due to the alleged fraud [1] - The nature of the allegations has not been detailed in the provided content, but the filing indicates serious concerns regarding the company's financial practices [1] - The outcome of this lawsuit could have significant implications for Perrigo's stock performance and investor confidence [1]

Core Viewpoint - A class action lawsuit has been filed against Perrigo Company plc for securities fraud, alleging that the company made misleading statements regarding its infant formula business and failed to disclose significant operational issues [1][11]. Summary by Sections Lawsuit Details - The lawsuit was filed in the U.S. District Court for the Southern District of New York on behalf of shareholders who acquired Perrigo securities between February 27, 2023, and November 4, 2025 [1]. - Plaintiffs are pursuing claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1]. Financial Performance and Issues - In November 2022, Perrigo acquired Nestlé's Gateway infant formula plant and the rights to the Good Start brand for $170 million [3]. - On February 27, 2024, Perrigo reported a 50% decline in earnings per share compared to the previous year, attributing this to remediation costs in the infant formula business, which were estimated to be an additional $35 million to $45 million [4]. - Following this announcement, Perrigo's share price fell by $4.87, or 15.14%, closing at $27.30 [5]. - On May 7, 2024, the company reported a 34.5% decrease in net sales for the first quarter, with gross margin declining by 90 basis points [6]. - The share price dropped by $3.28, or 9.8%, to close at $30.15 on the same day [7]. - On August 6, 2025, Perrigo disclosed that production issues led to scrapping approximately $11 million of inventory, resulting in a share price decline of $3.01, or 11.31%, to close at $23.61 [8]. - On November 5, 2025, Perrigo announced a strategic review of its infant formula business and slashed its fiscal year 2025 outlook, cutting net sales growth guidance to -2.5% to -3% from a previous expectation of 0% to 3% [9]. - The stock price fell by $5.09, or 25.2%, to close at $15.10 on the same day [10]. Allegations in the Lawsuit - The lawsuit alleges that Perrigo's management made materially false and misleading statements and failed to disclose adverse facts about the infant formula business, including: 1. Significant underinvestment in maintenance and operational improvements [11]. 2. The need for substantial capital expenditures beyond stated estimates for remediation [11]. 3. Manufacturing deficiencies in the infant formula facility [11]. 4. Overstated financial results, including earnings and cash flow [11]. 5. Misleading positive statements regarding the company's business and prospects [11].

Core Insights - Perrigo Company plc (NYSE:PRGO) is recognized as one of the 15 Best 52-Week Low Dividend Stocks to Invest in [1] - Canaccord has maintained a Buy rating on Perrigo while reducing its price target from $40 to $20, citing weaker-than-expected sales despite Q3 results beating expectations [2] - The company reported Q3 2025 revenue of $1.04 billion, a decline of 4.06% year-over-year, with operating income decreasing to $73 million from $80 million [3] Financial Performance - Q3 2025 revenue was $1.04 billion, down 4.06% compared to the same quarter last year [3] - Operating income for Q3 2025 was $73 million, a decrease from $80 million in the previous year [3] - The company experienced soft over-the-counter (OTC) consumption but gained market share in five of seven store-brand categories [3] Strategic Developments - Perrigo announced a strategic review of its infant formula business, focusing on higher-margin branded products due to challenges with quality issues and contamination risks in manufacturing [4] - The company is a leading supplier of store-brand baby formula, which is sold at lower prices compared to branded options [4] Company Overview - Perrigo is a leading consumer health company with over a century of experience in delivering high-quality health and wellness solutions, primarily in North America and Europe [5]

Core Insights - Holzer & Holzer, LLC is investigating Perrigo Company plc for potential compliance issues with federal securities laws following a disappointing earnings report and lowered full-year guidance [1] - Perrigo's third-quarter earnings revealed a 4.4% decline in organic net sales, attributed to a 1.6% decrease from the global OTC business and a 2.8% decline from businesses under review, specifically Oral Care and Infant Formula [1] Financial Performance - For the third quarter ended September 27, 2025, Perrigo reported a 4.4% decline in organic net sales [1] - The decline in organic net sales was impacted by a 1.6% decrease from the global OTC business due to soft category consumption [1] - Additionally, a 2.8% decline was noted from businesses under review, particularly in Oral Care and Infant Formula [1] Stock Market Reaction - Following the earnings announcement and guidance revision, Perrigo's stock price experienced a drop [1]

Core Viewpoint - Glancy Prongay & Murray LLP has initiated an investigation into Perrigo Company plc regarding potential violations of federal securities laws affecting investors [1] Summary by Relevant Sections - **Investigation Announcement** - The law firm is representing investors who may have incurred losses related to Perrigo Company plc [1] - **Investor Call to Action** - Investors who lost money on Perrigo Company plc are encouraged to inquire about pursuing claims to recover their losses [1]